Baird raised the firm’s price target on AdaptHealth to $16 from $14 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results and believe the shares are currently undervalued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AHCO:
